Oral Hyaluronic Acid in Osteoarthritis and Low Back Pain: A Systematic Review.

Q4 Medicine

Mediterranean Journal of Rheumatology Pub Date : 2024-12-31 eCollection Date: 2024-12-01 DOI:10.31138/mjr.240724.oha

Jozélio Freire de Carvalho, Josy Davidson

{"title":"Oral Hyaluronic Acid in Osteoarthritis and Low Back Pain: A Systematic Review.","authors":"Jozélio Freire de Carvalho, Josy Davidson","doi":"10.31138/mjr.240724.oha","DOIUrl":null,"url":null,"abstract":"Background: Hyaluronic acid (HA) has been largely used in clinical practice for rheumatic diseases. However, the effects of oral HA on these diseases are poorly understood.Aim: To review articles evaluating oral HA's effects on rheumatic patients.Methods: PubMed was searched for articles on oral HA and rheumatic diseases between 1966 and May 2024.Results: Eleven articles were found with 597 patients. The diseases investigated were OA (n=10) and low back pain (n=1). Age varied from 40 to 70 years old, and female gender ranged from 43% to 75%. Follow-up ranged from 4 weeks to 12 months. The oral HA dosage varied from 30 mg to 300 mg/day. Concerning outcome, 9/11 articles observed improvement in rheumatic diseases in the following parameters: VAS pain, WOMAC, joint function, SF-36, Lequesne index, and stiffness. Two studies evaluated cytokines and observed a reduction of them after oral HA therapy. Adverse effects were rare and mild.Conclusion: Oral HA seems to be a safe and effective therapy for OA and low back pain patients, although more studies should be done on the latter condition.","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 4","pages":"557-562"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11778613/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mediterranean Journal of Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31138/mjr.240724.oha","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hyaluronic acid (HA) has been largely used in clinical practice for rheumatic diseases. However, the effects of oral HA on these diseases are poorly understood.

Aim: To review articles evaluating oral HA's effects on rheumatic patients.

Methods: PubMed was searched for articles on oral HA and rheumatic diseases between 1966 and May 2024.

Results: Eleven articles were found with 597 patients. The diseases investigated were OA (n=10) and low back pain (n=1). Age varied from 40 to 70 years old, and female gender ranged from 43% to 75%. Follow-up ranged from 4 weeks to 12 months. The oral HA dosage varied from 30 mg to 300 mg/day. Concerning outcome, 9/11 articles observed improvement in rheumatic diseases in the following parameters: VAS pain, WOMAC, joint function, SF-36, Lequesne index, and stiffness. Two studies evaluated cytokines and observed a reduction of them after oral HA therapy. Adverse effects were rare and mild.

Conclusion: Oral HA seems to be a safe and effective therapy for OA and low back pain patients, although more studies should be done on the latter condition.

查看原文本刊更多论文

口服透明质酸治疗骨关节炎和腰痛：系统综述。

背景：透明质酸（HA）已广泛应用于风湿病的临床治疗。然而，口服透明质酸对这些疾病的影响尚不清楚。目的：回顾评价口服透明质酸对风湿病患者疗效的文献。方法：检索1966年至2024年5月间有关口腔HA和风湿病的文献。结果：共发现文献11篇，597例。调查的疾病为OA （n=10）和腰痛（n=1）。年龄40 ~ 70岁，女性占43% ~ 75%。随访时间为4周到12个月。口服透明质酸的剂量从30毫克到300毫克/天不等。关于结局，9/11文章观察到以下参数对风湿病的改善：VAS疼痛、WOMAC、关节功能、SF-36、Lequesne指数和僵硬度。两项研究评估了细胞因子，并观察到口服HA治疗后细胞因子的减少。不良反应罕见且轻微。结论：口服透明质酸似乎是OA和腰痛患者的一种安全有效的治疗方法，尽管对后者的研究还需要更多的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊